Immugenia
Immugenia is an early-stage immuno-oncology company developing innovative CAR therapy approaches by engineering hematopoietic stem cells to treat cancer and prevent relapses. The company combines the properties of stem cells and gene therapy to develop long-lasting cancer treatments, with a focus on making therapies more accessible through in vivo administration. Their proprietary technology allows for selective expression of CAR in T and NK cells, leveraging their activity against cancer, and aims to address current challenges in CAR T-cell therapy such as relapse, toxicity, and efficacy. The company is actively involved in collaborative research projects and participates in major industry events to advance cancer immunotherapy.
Industries
Nr. of Employees
small (1-50)
Immugenia
Products
CAR-HSC — Pre-B Acute Lymphoblastic Leukemia (CD22)
Preclinical HSC-based program encoding CAR constructs targeting CD22 to produce persistent CAR-expressing immune lineages for treatment of precursor-B acute lymphoblastic leukemia.
CAR-HSC — Rhabdomyosarcoma (B7-H3)
Preclinical HSC-based program encoding CAR constructs targeting B7-H3 for pediatric rhabdomyosarcoma, progressed to proof-of-concept stage in preclinical studies.
CAR-HSC — Glioblastoma (EGFRvIII)
Discovery-stage HSC-based CAR program directed at EGFRvIII for glioblastoma using stem-cell-derived CAR-T and CAR-NK approaches to address solid tumor indications.
In vivo CAR delivery program
Discovery-stage program exploring systemic administration of gene delivery vehicles combined with immune-cell-specific regulatory elements to induce CAR expression directly in patients' immune cells and/or mobilized HSCs.
CAR-HSC — Pre-B Acute Lymphoblastic Leukemia (CD22)
Preclinical HSC-based program encoding CAR constructs targeting CD22 to produce persistent CAR-expressing immune lineages for treatment of precursor-B acute lymphoblastic leukemia.
CAR-HSC — Rhabdomyosarcoma (B7-H3)
Preclinical HSC-based program encoding CAR constructs targeting B7-H3 for pediatric rhabdomyosarcoma, progressed to proof-of-concept stage in preclinical studies.
CAR-HSC — Glioblastoma (EGFRvIII)
Discovery-stage HSC-based CAR program directed at EGFRvIII for glioblastoma using stem-cell-derived CAR-T and CAR-NK approaches to address solid tumor indications.
In vivo CAR delivery program
Discovery-stage program exploring systemic administration of gene delivery vehicles combined with immune-cell-specific regulatory elements to induce CAR expression directly in patients' immune cells and/or mobilized HSCs.
Services
Joint R&D collaborations with academic, research institute, and industry partners to advance preclinical development of stem-cell-based CAR therapies and complementary technologies.
Engagement in consortium-funded pediatric oncology projects and presentation of technology at industry summits to support translation and partnership formation.
Joint R&D collaborations with academic, research institute, and industry partners to advance preclinical development of stem-cell-based CAR therapies and complementary technologies.
Engagement in consortium-funded pediatric oncology projects and presentation of technology at industry summits to support translation and partnership formation.
Expertise Areas
- Stem-cell-based immunotherapy
- Cell-type-specific promoter design
- Hematopoietic stem cell engineering
- In vivo immune-cell gene delivery
Key Technologies
- Synthetic cell-type-specific promoters
- Hematopoietic stem cell genetic modification
- Chimeric antigen receptor constructs
- Lentiviral-type vector engineering
News & Updates
Immugenia was selected to participate in the Johnson & Johnson Gene Therapy Summit in San Francisco on February 22, 2024, where they showcased their innovative technology to the gene therapy community of the West Coast.
Immugenia was invited to present their technology at the Gene Therapy Summit, highlighting their advancements in in vivo CAR delivery and stem cell engineering.
Immugenia was selected to participate in the Johnson & Johnson Gene Therapy Summit in San Francisco on February 22, 2024, where they showcased their innovative technology to the gene therapy community of the West Coast.
Immugenia was invited to present their technology at the Gene Therapy Summit, highlighting their advancements in in vivo CAR delivery and stem cell engineering.